A further investigation is needed to validate the predictive, prognostic, and pharmacodynamic roles of IgE in COPD, especially to determine if omalizumab, a monoclonal antibody that binds IgE, could have a role in COPD management in the future. The gene discussed is IGHE; the disease is chronic obstructive pulmonary disease.